Damico Jennifer B.'s Form 4 filing
Pfizer Inc (PFE) · filed Mar 17, 2023
- Accession no.
- 0001225208-23-004094
- Filed
- Mar 17, 2023
- Trade date
- Feb 24-Mar 15, 2023
- Filing delay
- 21 daysLate
- Rule 10b5-1 plan
- Not on the form (before 2023)
This filing lists 2 non-derivative transactions and 1 derivative transaction. Open-market sales total $396.7K. It was filed 21 days after the trade, past the 2-business-day deadline.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Damico Jennifer B.CIK 0001805617 | Officer (SVP & Controller) |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Feb 24, 2023 | Common Stock | FTax withholdingDisposed | −360 | $41.75 | −$15,030 | 16,383 | Direct | |
| Mar 15, 2023 | Common Stock | SSaleDisposed | −9,912 | $40.02 | −$396,678.24 | 9,003 | Direct |
Derivative securities (Table II)
Options, warrants, restricted stock units and similar. Shares are the underlying shares; price and value are for the derivative itself, and the holding after is in derivative units.
| Trade date | Security | Transaction | Underlying shares | Unit price | Value | Held after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Mar 15, 2023 | Common Stock | AGrant or awardAcquired | +451 | $40.28 | +$18,166.28 | 21,176 | Direct |
Footnotes and remarks
Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.
No transaction price on this filing refers to a footnote.